#BiologicsManufacturing #PeptideDevelopment #MicrobialManufacturing #GLP1Innovation #DrugSubstance #GMPManufacturing
Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
Another factor that affects the cost is the prescribed dosage and treatment frequency
It enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, and increases nitric oxide production by upregulating nitric oxide synthase (NOS) gene and protein expression
Symptoms to watch for include a lump in the neck, trouble swallowing or hoarseness
